ArticleJournal of clinical microbiology2018
Comparative Analysis of the Wako β-Glucan Test and the Fungitell Assay for Diagnosis of Candidemia and Pneumocystis jirovecii Pneumonia.
Article in Journal of clinical microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 69 citations in OpenAlex.
- Evaluating the sensitivity of the Wako β-D-glucan assay for the diagnosis of candidemia caused by Candida parapsilosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Dynamics of 1,3-β-D-Glucan in Invasive Candidiasis: A Narrative Review of Microbiological Aspects and Diagnostic Implications.Antibodies (Basel, Switzerland) · 2026Review
- Diagnostics for human pathogenic fungal infections: Current status and future prospects.hLife · 2026Review
- Combined Serum (1,3)-β-D-Glucan and Oral Wash PCR as a Noninvasive Diagnostic Strategy for Early Detection ofOpen forum infectious diseases · 2026Article
- Advances in pathogen detection ofInfectious medicine · 2025Review
- Use of interferon-gamma release assay (IGRA) and CXCL-10/IP-10 for latent tuberculosis infection (LTBI) screening in chronic kidney disease and hemodialysis patients.BMC infectious diseases · 2025Article
- β-D-Glucan Testing in Candidemia: Determinants of Positivity and Association With Mortality.Mycoses · 2025Article
- Evaluation of Serum Biomarkers for Improved Diagnosis of Candidemia.Journal of fungi (Basel, Switzerland) · 2025Article
- An overview of the laboratory diagnosis ofJournal of clinical microbiology · 2025Review
- Species-Specific Sensitivity and Levels of Beta-D-Glucan for the Diagnosis of Candidemia-A Systematic Review and Meta-Analysis.Journal of fungi (Basel, Switzerland) · 2025Review
- Community pharmacy-led point-of-care testing (POCT): expanding roles and strengthening health systems in low- and middle-income countries (LMICs).Journal of pharmaceutical policy and practice · 2025Article
- Unraveling the Gut Microbiota: Implications for Precision Nutrition and Personalized Medicine.Nutrients · 2024Review
- Posaconazole-hemp seed oil loaded nanomicelles for invasive fungal disease.Scientific reports · 2024Article
- Candent issues in pneumonia. Reflections from the Fifth Annual Meeting of Spanish Experts 2023.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Review
- Evaluation of a newer (1, 3)-β-D-glucan chemiluminescent immunoassay for invasive candidiasis: A study from a tertiary care center.Current medical mycology · 2024Article
- Outbreaks of Fungal Infections in Hospitals: Epidemiology, Detection, and Management.Journal of fungi (Basel, Switzerland) · 2023Review
- Emergence of microbial infections in some hospitals of Cairo, Egypt: studying their corresponding antimicrobial resistance profiles.BMC infectious diseases · 2023Article
- Diagnosis of invasive fungal infections: challenges and recent developments.Journal of biomedical science · 2023Review
- Sputum handling for rheology.Scientific reports · 2023Article
- The Comparative Evaluation of the Fujifilm Wako β-Glucan Assay and Fungitell Assay for Diagnosing Invasive Fungal Disease.Journal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1→3)-β-d-Glucan (BDG) is a biomarker for invasive fungal disease. Until now, all BDG data in the Western Hemisphere were obtained using the Fungitell assay (FA). How it compares to the Wako β-glucan test (GT), which was recently launched in Europe, is largely unknown. We conducted a case-control study to compare the two assays in serum samples from 120 candidemia and 63
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.